Medicenna Therapeutics Corp MDNA
News
Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026
Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
